NCT00068588View on ClinicalTrials.gov

GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
BIOLOGICAL

GTI-2040

Given IV

DRUG

capecitabine

Given orally

Trial Locations (1)

95817

University of California Davis Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00068588 - GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter